Antibody-drug conjugates (ADCs) are targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, allowing for selective delivery of the drug to cancer cells while minimizing damage to healthy tissues. This approach enhances therapeutic efficacy and reduces systemic toxicity, representing a significant advancement in oncology treatment strategies.